🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

STrategies for Anticoagulation in Patients With thRombocytopenia and Cancer-associated Thrombosis

RecruitingPhase 4Ages 18 Years - anyAllTzu-Fei Wang
NCT05255003 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Patients with cancer are prone to have blood clots, which are usually treated with blood thinners. The main complication of blood thinners is bleeding. This is especially a concern when the number of platelets in the blood is lower than 50,000 per microliter. The role of platelets is to stop bleeding, so when the number of platelets is low, patients are at a higher risk of bleeding. Cancer patients are prone to have lower platelet numbers due to cancer therapies and/or cancer itself. It is not clear what the best treatment is for cancer patients who need blood thinners for a blood clot but have low platelet counts. The investigators plan to do a small study called a pilot study to help plan for a larger study in such patients. In the pilot study, investigators will include 50 patients with cancer, low platelet counts, and a blood clot diagnosed within 2 weeks. Patients will be randomly

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Adult patients (age ≥ 18) with active malignancy (malignancy diagnosed or treated within the previous 6 months, or progressive/relapsed); 2. Objectively confirmed VTE within last 14 days for which therapeutic anticoagulation is planned; 3. Thrombocytopenia with a platelet count \< 50,000/uL from cancer therapy or malignancy itself; 4. Able to provide written informed consent Exclusion Criteria: 1. Receipt of anticoagulant for index VTE with platelet count \< 50,000/uL for \> 72 hours; 2. Superficial vein thrombosis only; 3. Life expectancy \< 1 month (as judged by the treating physicians); 4. Creatinine clearance \< 30 ml/min; 5. Contraindication to LMWH such as a history of heparin induced thrombocytopenia; 6. Thrombocytopenia from other causes, such as thrombotic microangiopathy, immune thrombocytopenia, disseminated intravascular coagulation; 7. Previously documented history of refractoriness to platelet transfusion secondary to HLA antibodies; 8. Refusal of blood products; 9. Anticoagulation at any dose is deemed unsafe (i.e. active bleeding or bleeding disorders)
💊

What it tests

  • Enoxaparin
  • Dalteparin
  • Tinzaparin
📍

Where

4 sites
University of Alberta
Edmonton, Canada
The Ottawa Hospital
Ottawa, Canada
Niagara Health - St. Catharines Site
Saint Catharines, Canada
Windsor Regional Hospital
Windsor, Canada
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy